Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data
Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.
How this was made
The 30-second read
Why it matters
The data positions Takeda's zasocitinib as a potentially market‑leading oral therapy for plaque psoriasis, likely prompting analyst upgrades and price re‑ratings.
Market read
First disclosure of superior Phase 3 efficacy for an oral psoriasis drug, likely to move Takeda's stock and affect the dermatology biotech niche.
What to watch
Regulatory review timelines and reimbursement landscape could delay commercial impact despite strong data.
Background
The article summarizes first‑time head‑to‑head Phase 3 data presented at EADV 2026, highlighting efficacy differences between two oral TYK2 inhibitors.
Ticker impact
Takeda reported phase 3 LATITUDE trial data showing zasocitinib achieved PASI 100 in 36.5% vs 13.9% for deucravacitinib.
likely upside as investors price in superior efficacy versus competitor
First disclosure of head‑to‑head Phase 3 data with statistically significant superiority; market typically reacts favorably to such breakthroughs.
Market effects
May boost sentiment for the broader dermatology/biotech sector as oral TYK2 inhibitors gain credibility.
Potentially supportive for Japanese pharma equities, especially Takeda and peers developing similar agents.
Could influence global investors tracking innovative psoriasis therapies and oral small‑molecule pipelines.
Counterpoint
If safety concerns (e.g., higher acne incidence) outweigh efficacy, the market may temper enthusiasm.
Key entities
- CompanyTakeda Pharmaceutical Company
Developer of zasocitinib, reporting the trial results.
- DrugZasocitinib
Investigational next‑generation TYK2 inhibitor showing superior PASI 100 rates.
- DrugDeucravacitinib
Competitor TYK2 inhibitor used as comparator in the trial.
